डैल्फैम्प्रिडिन के इंटरैक्शन

…with: • type 2 diabetes with microalbuminuria, • serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions… (एप्लेरेनोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. (एमिलोराइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride : Concomitant use is not recommended. (ग्लाइकोपाइरोलेट लेबल, दवाओं के इंटरैक्शन)

Information for patients Patients who receive spironolactone and hydrochlorothiazide tablets should be advised to avoid potassium supplements and foods containing high levels of potassium including salt substitutes. (स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइड लेबल, सावधानियां)

Coadministration of AVALIDE with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe. (इर्बेसार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां और सावधानियां)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions ( 7.3 )]. (एनालाप्रिल लेबल, चेतावनियां और सावधानियां)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (एनालाप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (एनालाप्रिलैट लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (एम्लोडिपिन और वाल्सार्टन लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (एलिस्किरेन लेबल, चेतावनियां और सावधानियां)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.3) ] . (ओल्मेसार्टन लेबल, चेतावनियां और सावधानियां)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Co-administration of candesartan cilexetil and hydrochlorothiazide tablets with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (कैप्टोप्रिल लेबल, दवाओं के इंटरैक्शन)

Hyperkalemia Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (टेल्मिसार्टन लेबल, चेतावनियां और सावधानियां)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (टेल्मिसार्टन और एम्लोडिपिन लेबल, चेतावनियां और सावधानियां)

Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e.g., dofetilide, dalfampridine, and cisplatin) [see Clinical Pharmacology ( 12.3 )]. (ट्रिलासिक्लिब लेबल, दवाओं के इंटरैक्शन)

Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. (ट्रैंडोलाप्रिल लेबल, दवाओं के इंटरैक्शन)

Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin, Table 8 ) [see Contraindications ( 4 ), Drug Interactions ( 7.3 )] . (डोलुटेग्राविर लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus and the concomitant use of agents such as potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.2) ] . (पेरिंडोप्रिल लेबल, चेतावनियां और सावधानियां)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (पोटैशियम आयोडाइड लेबल, दवाओं के इंटरैक्शन)

Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. (फोसिनोप्रिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Potassium supplements and potassium-sparing diuretics As noted above (“Derangements of Serum Electrolytes”), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged. (फोसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Monitor serum potassium levels; use potassium supplements if necessary. (फ्लुड्रोकॉर्टिसोन लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Potassium Supplements and Potassium-Sparing Diuretics: Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. (मोएक्सिप्रिल लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (लिसिनोप्रिल लेबल, चेतावनियां और सावधानियां)

Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (लिसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7.1 ) (वाल्सार्टन लेबल, दवाओं के इंटरैक्शन)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (वाल्सार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (साइक्लोस्पोरिन लेबल, दवाओं के इंटरैक्शन)

OCT2 Inhibitors Concurrent treatment with OCT2 inhibitors, such as cimetidine, may cause increased exposure to dalfampridine [ see Clinical Pharmacology (12.3) ]. (डैल्फैम्प्रिडिन लेबल, दवाओं के इंटरैक्शन)

Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)] . (सैक्यूबिट्रिल और वाल्सार्टन लेबल, दवाओं के इंटरैक्शन)

This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (स्पिरोनोलैक्टोन लेबल, चेतावनियां और सावधानियां)

Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (डोब्यूटामिन लेबल, दवाओं के इंटरैक्शन)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (बुमेटेनाइड लेबल, चेतावनियां)

Interactions Common for Both Benazepril and Hydrochlorothiazide Potassium Supplements and Potassium -Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. (बेनाज़ेप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (मिलरिनोन लेबल, दवाओं के इंटरैक्शन)

Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride. (हायोसायमिन लेबल, दवाओं के इंटरैक्शन)

Baclofen No interaction was identified between dalfampridine and baclofen [see Clinical Pharmacology (12.3) ]. (डैल्फैम्प्रिडिन लेबल, दवाओं के इंटरैक्शन)